If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDeltex Medical Regulatory News (DEMG)

  • There is currently no data for DEMG

Issue of Equity

18 Jan 2024 17:01

RNS Number : 2057A
Deltex Medical Group PLC
18 January 2024
 

18 January 2024

 

Deltex Medical Group plc

("Deltex Medical", the "Company" or the "Group")

 

Issue of equity to satisfy equity-settled non-executive directors' fees

 

The Board of Deltex Medical (AIM: DEMG), announces the issue of 49,372,352 new ordinary shares of 1p each in the capital of the Company (the "Ordinary Shares"), at an issue price of 0.17 pence per new Ordinary Share (the "Issue Price"). The Issue Price represents the Company's closing mid-market price on 17 January 2024.

 

The new Ordinary Shares are being issued in order to satisfy the fees of certain current and former non-executive directors for the year ending 31 December 2023 ("Fee Shares"), as has been done in previous years.

 

A total of 12,941,176 Fee Shares will be issued to former non-executive director Mark Wippell and a total of36,431,176 Fee Shares will be issued to current non-executive directors as set out below:

 

Resultant holding post Fee Shares

Director

Current Ordinary Shares held

Fee Shares issued

Ordinary Shares held

As a percentage of the enlarged share capital on Admission

Nigel Keen

332,267,649

22,313,529

354,581,178

18.70%

Chris Jones

6,479,109

14,117,647

20,596,756

1.09%

 

Under the contract with Nigel Keen, he or the Company can opt to settle his fees (plus employer's national insurance) by the issue of new ordinary shares at the share price at the time of issue and the same applies to Chris Jones' and Ben Carswell's contracts for up to half of their fees. These share issues are expected to occur on an annual basis when permitted.

 

Application for admission to trading and total voting rights

 

Application has been made for 49,372,352 new Ordinary Shares to be admitted to trading on AIM, which is expected to take effect on or around 24 January 2024 ("Admission").

 

Following Admission, the Company's issued share capital will comprise 1,896,025,700 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

For further information, please contact:

 

Deltex Medical Group plc

01243 774 837

Nigel Keen, Chairman

 investorinfo@Deltexmedical.com

Andy Mears, Chief Executive

Natalie Wettler, Group Finance Director

Nominated Adviser and Broker

Allenby Capital Limited

020 3328 5656

 

Jeremy Porter / Vivek Bhardwaj (Corporate Finance)

info@allenbycapital.com

Tony Quirke / Stefano Aquilino (Sales & Corporate Broking)

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

 

1. 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

PDMRs:

Nigel Keen

Non-Executive Director - Chairman

Chris Jones

Non-Executive Director

 

 

2. 

Reason for the Notification

a)

Position/status

See 1a) above

b)

Initial notification/Amendment

Initial Notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Deltex Medical Group Plc

b)

LEI

213800XN34P6LI8J6M39

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary shares of 0.1p each in Deltex Medical Group Plc

 

Identification code

ISIN: GB0059337583

b)

Nature of the transaction

Fee shares

c)

Price(s) and volume(s)

Name

Price(s)

Volume(s)

Nigel Keen

0.17p

22,313,529

Chris Jones

0.17p

14,117,647

d)

Aggregated information:

- Aggregated volume

36,431,176

- Price

0.17p

e)

Date of the transaction

18 January 2024

f)

Place of the transaction

Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOESFUFMAELSEIF
Date   Source Headline
24th Dec 20127:00 amRNSNHS sets requirements for Fluid Management
10th Dec 20127:00 amRNSNew study supports the importance of ODM
29th Nov 20127:00 amRNSStudy reinforces CardioQ-ODM competitive advantage
31st Oct 20129:52 amRNSDirector/PDMR Shareholding
25th Oct 20124:47 pmRNSAdditional Listing
23rd Oct 20127:00 amRNSNHS South Innovation Plan
19th Oct 20127:00 amRNSEnhanced Recovery Update
10th Oct 20124:25 pmRNSGrant of options
10th Oct 20124:23 pmRNSIssue of Equity and TVR
19th Sep 20127:00 amRNSInterim Results
9th Aug 20128:23 amRNSHolding(s) in Company
6th Jul 20127:00 amRNSPre-close update on six months ended 30 June 2012
3rd Jul 20127:00 amRNSERP backs wide adoption of CardioQ-ODM
29th Jun 201210:13 amRNSDirector/PDMR Shareholding
22nd May 20124:54 pmRNSIssue of Equity
2nd May 20121:00 pmRNSResult of AGM
16th Apr 20129:35 amRNSHolding(s) in Company (Replacement to 10/04/12)
16th Apr 20129:23 amRNSHolding(s) in Company
10th Apr 20124:58 pmRNSHolding(s) in Company
5th Apr 201211:42 amRNSDirector/PDMR Shareholding
4th Apr 20127:00 amRNSIssue of Equity
29th Mar 20127:00 amRNSCardioQ-ODM in emergency abdominal surgery
26th Mar 20128:34 amRNSHolding(s) in Company
23rd Mar 20122:08 pmRNSHolding(s) in Company
21st Mar 20124:48 pmRNSIssue of Equity
16th Mar 201212:59 pmRNSIssue of Equity
14th Mar 20127:00 amRNSCardioQ Canadian Implementation Progress
7th Mar 20127:00 amRNSDeltex Medical awarded NHS Supply Chain tender
7th Mar 20127:00 amRNSResults Summary for the year ended 31 Dec 2011
5th Mar 20127:00 amRNSITAPP promotes intra-operative fluid monitoring
1st Mar 20128:29 amRNSHolding(s) in Company
22nd Feb 20127:00 amRNSDeltex Medical selected for US evaluation project
5th Jan 20127:00 amRNSPre-close update on the year ended 31 Dec 2011
21st Dec 20112:13 pmRNSCorrection - Issue of Equity
21st Dec 20117:00 amRNSBenefits of CardioQ-ODM in bladder surgery
14th Dec 20117:00 amRNSIssue of Equity
9th Dec 20119:00 amRNSNCEPOD supports NICE guidance on CardioQ-ODM
7th Dec 20114:32 pmRNSIssue of Equity
7th Dec 20114:01 pmRNSDirector/PDMR Shareholding
6th Dec 20117:00 amRNSNHS Innovation Review prioritises ODM
30th Nov 201112:13 pmRNSIssue of Equity
1st Nov 20118:22 amRNSDirector/PDMR Shareholding
28th Sep 20115:16 pmRNSGrant of Options
28th Sep 20115:06 pmRNSDirectors' Shareholdings / Issue of Equity
14th Sep 20117:00 amRNSInterim Results
18th Jul 20117:00 amRNSTrading Statement
17th Jun 201110:24 amRNSTotal Voting Rights - Correction
6th Jun 20115:46 pmRNSAdditional Listing
31st May 201112:18 pmRNSHolding(s) in Company
19th May 20112:35 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.